Evidence map›Paper›PMID 35269839›Full record

ArticleInternational journal of molecular sciences2022

Deyan Yavorov-Dayliev, Fermín I Milagro, Josune Ayo, María Oneca, Paula Aranaz

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07371325 (Efficacy of Pediococcus Acidilactici as add-on to Antipsychotic Drugs on Metabolic Syndrome Disturbances in First-episode Psychosis and Schizophrenia Spectrum Disorders. A Double-blind Placebo-controlled Trial.), which is not on this map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07371325 nacompletednot on this mapstarted 2024, after this paper: background citation

Efficacy of Pediococcus Acidilactici as add-on to Antipsychotic Drugs on Metabolic Syndrome Disturbances in First-episode Psychosis and Schizophrenia Spectrum Disorders. A Double-blind Placebo-controlled Trial.

TypeinterventionalSponsorManuel Jesús Cuesta ZuritaRan2024 to 2026Enrolled36ConditionsSCHIZOPHRENIA 1 (Disorder), Metabolic Abnormalities, Postbiotic SupplementArmsPediococcus acidilactici, pA1c®HI postbiotic supplementation taking participants, Atypical antipsychotics (AAP)
3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 28 citations in OpenAlex.

  1. Article
  2. Article
  3. Journal of agricultural and food chemistry · 2025
    Article
  4. Postbiotic pA1cInternational journal of molecular sciences · 2025
    Article
  5. Heat-InactivatedInternational journal of molecular sciences · 2025
    Article
  6. Anti-Obesity Properties of a Novel Probiotic Strain ofInternational journal of molecular sciences · 2025
    Article
  7. Efficacy ofFrontiers in immunology · 2025
    Article
  8. The Probiotic StrainMicroorganisms · 2024
    Article
  9. Review
  10. International journal of molecular sciences · 2024
    Review
  11. Bioscience of microbiota, food and health · 2024
    Article
  12. Article
  13. Article
  14. Pharmaceutics · 2023
    Article
  15. Application ofInternational journal of molecular sciences · 2023
    Review
  16. Spray Drying Encapsulation ofFoods (Basel, Switzerland) · 2022
    Article
  17. Review
  18. Gut microbiota and obesity: New insights.Frontiers in nutrition · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Deyan Yavorov-DaylievGenbioma Aplicaciones SL. Polígono Industrial Noain-Esquiroz, Calle S, Nave 4, 31191 Esquíroz, Spain.ORCID 0000-0002-7901-0695
Fermín I MilagroCenter for Nutrition Research, Faculty of Pharmacy and Nutrition, University of Navarra, 31008 Pamplona, Spain.ORCID 0000-0002-3228-9916
Josune AyoGenbioma Aplicaciones SL. Polígono Industrial Noain-Esquiroz, Calle S, Nave 4, 31191 Esquíroz, Spain.
María OnecaGenbioma Aplicaciones SL. Polígono Industrial Noain-Esquiroz, Calle S, Nave 4, 31191 Esquíroz, Spain.
Paula AranazCenter for Nutrition Research, Faculty of Pharmacy and Nutrition, University of Navarra, 31008 Pamplona, Spain.ORCID 0000-0002-1282-0079
Instituto de Salud Carlos III · ESNavarre Institute of Health Research · ESUniversidad de Navarra · ES

Funding

Centro de Investigación Biomédica en Red de la Fisiopatología de la Obesidad y Nutrición (CIBERobn). Institute of Health Carlos III, 28029 Madrid, Spain CB12/03/30002Government of Navarra (Ayudas para la contratación de doctorandos y doctorandas "Doctorados industriales 2020") [Reference: 0011-1408-2020-000010]Torres-Quevedo grants from the Spanish Ministry of Science and Innovation (Ayudas para contratos Torres Quevedo PTQ2019-010384 / AEI / 10.13039/501100011033
6 · The paper itself

Abstract

The increasing prevalence of metabolic syndrome-related diseases, including type-2 diabetes and obesity, makes it urgent to develop new alternative therapies, such as probiotics. In this study, we have used Caenorhabditis elegans under a high-glucose condition as a model to examine the potential probiotic activities of Pediococcusacidilactici CECT9879 (pA1c). The supplementation with pA1c reduced C. elegans fat accumulation in a nematode growth medium (NGM) and in a high-glucose (10 mM) NGM medium. Moreover, treatment with pA1c counteracted the effect of the high glucose by reducing reactive oxygen species by 20%, retarding the aging process and extending the nematode median survival (>2 days in comparison with untreated control worms). Gene expression analyses demonstrated that the probiotic metabolic syndrome-alleviating activities were mediated by modulation of the insulin/IGF-1 signaling pathway (IIS) through the reversion of the glucose-nuclear-localization of daf-16 and the overexpression of ins-6 and daf-16 mediators, increased expression of fatty acid (FA) peroxisomal β-oxidation genes, and downregulation of FA biosynthesis key genes. Taken together, our data suggest that pA1c could be considered a potential probiotic strain for the prevention of the metabolic syndrome-related disturbances and highlight the use of C. elegans as an appropriate in vivo model for the study of the mechanisms underlying these diseases.

Indexed as

Caenorhabditis elegans ProteinsMetabolic SyndromePediococcus acidilacticiAnimalsCaenorhabditis elegansForkhead Transcription FactorsGlucoseInsulinInsulin, Regular, HumanLongevitySignal TransductionCaenorhabditis elegans ProteinsForkhead Transcription FactorsGlucoseInsulinInsulin, Regular, HumanCaenorhabditis elegansdaf-16diabetesinsulin-signaling-pathwayobesityprobioticβ-oxidation

Identifiers

PMID35269839
PMCPMC8910957
OpenAlexW4214539451

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.